PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Beck, C.* ; Ramanujam, D.* ; Vaccarello, P.* ; Widenmeyer, F.* ; Feuerherd, M. ; Cheng, C.C.* ; Bomhard, A.* ; Abikeeva, T.* ; Schädler, J.* ; Sperhake, J.P.* ; Graw, M.* ; Safi, S.* ; Hoffmann, H.* ; Staab-Weijnitz, C.A. ; Rad, R.* ; Protzer, U. ; Frischmuth, T.* ; Engelhardt, S.*

Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage.

Nat. Commun. 14:4564 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Recent studies of severe acute inflammatory lung disease including COVID-19 identify macrophages to drive pulmonary hyperinflammation and long-term damage such as fibrosis. Here, we report on the development of a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), as a therapeutic means against pulmonary hyperinflammation and fibrosis. MicroRNA-21 is among the strongest upregulated microRNAs in human COVID-19 and in mice with acute inflammatory lung damage, and it is the strongest expressed microRNA in pulmonary macrophages. Chemical linkage of a microRNA-21 inhibitor to trimannose achieves rapid and specific delivery to macrophages upon inhalation in mice. RCS-21 reverses pathological activation of macrophages and prevents pulmonary dysfunction and fibrosis after acute lung damage in mice. In human lung tissue infected with SARS-CoV-2 ex vivo, RCS-21 effectively prevents the exaggerated inflammatory response. Our data imply trimannose-coupling for effective and selective delivery of inhaled oligonucleotides to pulmonary macrophages and report on a first mannose-coupled candidate therapeutic for COVID-19.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
16.600
0.000
2
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Genes
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2041-1723
e-ISSN 2041-1723
Zeitschrift Nature Communications
Quellenangaben Band: 14, Heft: 1, Seiten: , Artikelnummer: 4564 Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
Institute of Lung Health and Immunity (LHI)
POF Topic(s) 30203 - Molecular Targets and Therapies
80000 - German Center for Lung Research
30202 - Environmental Health
Forschungsfeld(er) Immune Response and Infection
Lung Research
PSP-Element(e) G-502700-003
G-501800-817
G-501600-001
G-502799-701
Förderungen DFG
European Union
BMBF
Bayerische Forschungsstiftung through CoVmiR
Deutsche Forschungsgemeinschaft (DFG)
German Federal Ministry of Education and Research BMBF
Freiburg Galaxy Team: Bjoern Gruening, Bioinformatics, University of Freiburg (Germany) - Collaborative Research Centre 992 Medical Epigenetics (DFG)
DOI 10.1038/s41467-023-40185-1
WOS ID 001040551400011
Scopus ID 85165974849
PubMed ID 37507393
Erfassungsdatum 2023-10-06
[➜Korrektur melden]